This fall, we shared the first clinical data on our beta-catenin:TCF inhibitor, FOG-001, at a series of medical meetings. In the coming months and years, more releases will follow, both for FOG-001 and the new candidates we are advancing in our pipeline. These will typically be formal and focused, usually in the form of presentations or posters. But in summarizing the high-level outcomes of the complex and multi-year efforts that go into discovering a new drug, these publications are necessarily forced to ignore the details, challenges, and innovations that define the actual day-to-day experience of our teams.
No two drug discovery programs are ever alike, but modality building comes with the added challenge of having no playbook or blueprint to guide us along the way. For many of us at Parabilis, the opportunity to explore a new continent of science is one of the most compelling and energizing aspects of what we do. Over the years, our culture has evolved to reflect the realities and needs of this mission: we are curious, collaborative, and driven, but above all else, we are learners and teachers. Nobody has walked these paths before, and we must always keep our minds open to the next piece of data.
In that spirit, we have created this space to serve as a home for the ideas and stories that we’ve wanted to share, but that don’t quite fit into our more formal presentations or press releases. The emphasis here still will be technical, but more broadly informative, covering topics like data science, experimentation, AI, equipment and infrastructure, and the craft of drug hunting. Some posts will reflect on general ideas or principles; others will dive into a specific technique or dataset. We’ll discuss what we know, what we don’t, and what makes our innovative modality so deeply compelling to us.
We hope you’ll join us on the journey!
Authored by John McGee, Platform Technology team member
